Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab With or Without Fianlimab in HPV(+) Head and Neck Cancer With Minimal-residual Disease
NCT07179315Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Jun 2026
- Primary completion
- Nov 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of fianlimab in head and neck cancer (HNC), sponsored by University of Chicago. Started Jun 2026; status: recruiting.
02
Drugs
fianlimab
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT07179315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07179315.